The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Interleukin–10 Expression and Function in Experimental Murine Liver Inflammation and Fibrosis
Open accessAbstract
Kupffer cells (KC) play a central role in the initiation and perpetuation of hepatic inflammation, which, if uncontrolled, can result in tissue damage, fibrosis, and cirrhosis. Interleukin–10 (IL–10) can inhibit a range of macrophage functions. We hypothesized that the transcription, synthesis, and release of IL–10 may influence the development of liver injury. Rat KC were activated in vitro with lipopolysaccharide (LPS), and expression of IL–10 mRNA compared with IL–13 and IL–1β by reverse–transcription polymerase chain reaction (RT–PCR). The effects of pretreatment with recombinant IL–10 (rIL–10) on KC phagocytosis, production of superoxide (SO), and tumor necrosis factor α (TNF–α) were examined by fluorescent activated cell sorter (FACS), reduction of ferricytochrome C, and bioassay, respectively. Rats were administered intraperitoneal carbon tetrachloride (CCl 4), and expression of IL–10 mRNA and protein in vivo compared with IL–13 and IL–1β by RT–PCR and immunoblotting. Results were correlated with histological inflammatory changes. Finally, IL–10 gene–deleted (IL–10-/-) mice and wild–type (WT) controls were administered intraperitoneal CCl 4 biweekly for up to 70 days, and the development of inflammation and fibrosis compared by scoring histological changes. IL–10 mRNA was up–regulated early, both in KC in vitro and in whole liver in vivo, concurrent with that of IL–1β. IL–10 was able to inhibit KC production of both SO and TNF–α in vitro, and this was achieved more effectively than IL–4 or IL–13; no such effects were seen on KC phagocytosis. After 70 days of treatment with CCl 4, IL–10-/- mice showed significantly more severe fibrosis and exhibited higher hepatic TNF–α levels than WT controls. These results suggest that IL–10 synthesized during the course of liver inflammation and fibrosis may modulate KC actions, and influence subsequent progression of fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C. G., & de Vries, J. E. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.5.1209 · Cited by 3,762
IL-10 inhibits cytokine production by activated macrophages
Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M., & O’Garra, A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.11.3815 · Cited by 2,888
Cited by
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
“Mice treated with IL-10 develop significantly less liver, lung and pancreatic fibrosis when challenged with carbon tetrachloride (CCl4), bleomcyin and cerulein, respectively [150–153].”
BackgroundHepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Cirrhosis-associated immune dysfunction
Albillos, A., Martin-Mateos, R., Van der Merwe, S., Wiest, R., Jalan, R., & Álvarez-Mon, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00520-7 · Cited by 447
The Role of the Anti-Inflammatory Cytokine Interleukin-10 in Tissue Fibrosis
Steen, E. H., Wang, X., Balaji, S., Butte, M. J., Bollyky, P. L., & Keswani, S. G. (2020) · Advances in Wound Care · doi:10.1089/wound.2019.1032 · Cited by 433
The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis
Elsharkawy, A. M., Oakley, F., & Mann, D. A. (2005) · Apoptosis · doi:10.1007/s10495-005-1055-4 · Cited by 419
Cytokine mediated tissue fibrosis
Borthwick, L. A., Wynn, T. A., & Fisher, A. J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.09.014 · Cited by 375
Fadok, V. A., Bratton, D. L., Guthrie, L., & Henson, P. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6847 · Cited by 366
Nelson, D. R., Lauwers, G. Y., Lau, J. Y. N., & Davis, G. L. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70134-x · Cited by 349
Liver fibrogenesis and the role of hepatic stellate cells: New insights and prospects for therapy
Li, D., & Friedman, S. (1999) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.1999.01928.x · Cited by 343
Hepatic fibrosis: molecular mechanisms and drug targets
Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P., & Mallat, A. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095906 · Cited by 325
The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease
Lim, Y.-S., & Kim, W. R. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.07.007 · Cited by 316
Bourdi, M., Masubuchi, Y., Reilly, T. P., Amouzadeh, H. R., Martin, J. L., George, J. W., Shah, A. G., & Pohl, L. R. (2002) · Hepatology · doi:10.1053/jhep.2002.30956 · Cited by 302
Advances in the Diagnosis, Pathogenesis, and Management of Autoimmune Hepatitis
Czaja, A. J., & Manns, M. P. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.053 · Cited by 280
Fang, B., Shi, M., Liao, L., Yang, S., Liu, Y., & Zhao, R. C. (2004) · Transplantation · doi:10.1097/01.tp.0000128326.95294.14 · Cited by 271
Fibrosis Related Inflammatory Mediators: Role of the IL‐10 Cytokine Family
Sziksz, E., Pap, D., Lippai, R., Béres, N. J., Fekete, A., Szabó, A. J., & Vannay, Á. (2015) · Mediators of Inflammation · doi:10.1155/2015/764641 · Cited by 265
Wallace, K., Burt, A. D., & Wright, M. C. (2008) · Biochemical Journal · doi:10.1042/bj20071570 · Cited by 262
Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells
Parekkadan, B., van Poll, D., Megeed, Z., Kobayashi, N., Tilles, A. W., Berthiaume, F., & Yarmush, M. L. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.150 · Cited by 252
Safadi, R., Ohta, M., Alvarez, C. E., Fiel, M. I., Bansal, M., Mehal, W. Z., & Friedman, S. L. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.062 · Cited by 239
The Role of Intestinal Endotoxin in Liver Injury: A Long and Evolving History
Nolan, J. P. (2010) · Hepatology · doi:10.1002/hep.23917 · Cited by 229
Attenuation of CCl 4 -induced hepatic fibrosis by GdCl 3 treatment or dietary glycine
Rivera, C. A., Bradford, B. U., Hunt, K. J., Adachi, Y., Schrum, L. W., Koop, D. R., Burchardt, E.-R., Rippe, R. A., & Thurman, R. G. (2001) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2001.281.1.g200 · Cited by 165
Schwabe, R. F., Schnabl, B., Kweon, Y. O., & Brenner, D. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6812 · Cited by 155
Zhang, X.-W., Mi, S., Li, Z., Zhou, J.-C., Xie, J., Hua, F., Li, K., Cui, B., Lv, X.-X., Yu, J.-J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14266 · Cited by 48
“Several studies inhibited IL-10 by genetic way, and found IL-10 depletion resulting in liver injury or fibrosis exacerbation [33, 34].”
Background
Metadata
- Authors
- Thompson, K., Maltby, J., Fallowfield, J., McAulay, M., Millward-Sadler, H., & Sheron, N.
- Venue
- Hepatology
- Published
- 1998-12
- Volume
- 28
- Issue
- 6
- Pages
- 1597-1606
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2062607785
- Cited by
- 236
- References
- 2
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.